{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:22:16Z","timestamp":1795029736980,"version":"4.10.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck LLC, Deerfield, IL, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data from the real-world REVIEW (Real-world EVidence and Insights into Experiences With eptinezumab) study demonstrated that, after starting treatment with eptinezumab, individuals with chronic migraine (CM) experienced double the number of good days per month and high rates of satisfaction with eptinezumab. This post-hoc analysis explored the associations between self-reported changes in good days per month and other health-related outcome measures and the utility of good days per month as a patient-centric measure of the composite impact of migraine and migraine treatment on an individual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>REVIEW was an observational, multi-site study designed to evaluate real-world experiences of patients treated with eptinezumab. A survey was administered to adults with CM who had completed\u2009\u2265\u20092 treatment cycles with eptinezumab. These post hoc analyses evaluated the impact of eptinezumab treatment on the ability to achieve a\u2009\u2265\u200950% and \u2265\u200975% increase in self-reported good days per month, and the association between these improvements and migraine symptoms, elements of daily living, overall well-being, and brain fog. Results are reported for the subgroups defined by the percentage change in self-reported good days per month after initiating eptinezumab treatment relative to before initiation (\u2265\u200975% increase vs.\u2009&lt;\u200975% and \u2265\u200950% increase vs.\u2009&lt;\u200950%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following eptinezumab initiation, \u2265\u200975% and \u2265\u200950% increases in good days per month were reported by 59\/92 (64%) and 70\/92 (76%) evaluable participants, respectively. Participants with \u2265\u200975% increase in good days per month also reported a greater positive impact on multiple migraine symptom domains (68%\u201390%), as well as select aspects of daily living and overall well-being (73%\u201390%) compared with participants with &lt;\u200975% increase (27%\u201361% and 18%\u201339%, respectively). Moderate to complete improvement in brain fog after eptinezumab was reported by 77% of participants in the \u2265\u200975% increase subgroup versus 42% in the &lt;\u200975% subgroup. Results were consistent for the \u2265\u200950% increase versus &lt;\u200950% subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following eptinezumab treatment, most participants reported substantial increases in good days per month, with those experiencing\u2009\u2265\u200975% improvement also reporting greater improvements across multiple migraine symptom domains, daily functioning, overall well-being, and brain fog. These real-world data underscore the importance of novel, patient-centered approaches to understand how preventive therapies can reduce multiple aspects of migraine burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02227-5","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:53:47Z","timestamp":1764140027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-5004","authenticated-orcid":false,"given":"Fawad A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-6144","authenticated-orcid":false,"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Soni-Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3248-7258","authenticated-orcid":false,"given":"S. Wald","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3767-7130","authenticated-orcid":false,"given":"Divya","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-8069","authenticated-orcid":false,"given":"Charles","family":"Argoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"2","key":"2227_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/head.14817","volume":"65","author":"JS McGinley","year":"2025","unstructured":"McGinley JS, Mangrum R, Gerstein MT, McCarrier KP, Houts CR, Buse DC et al (2025) Symptoms across the phases of the migraine cycle from the patient\u2019s perspective: results of the MiCOAS qualitative study. Headache 65(2):303\u2013314. https:\/\/doi.org\/10.1111\/head.14817","journal-title":"Headache"},{"issue":"7","key":"2227_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/head.14521","volume":"63","author":"R Mangrum","year":"2023","unstructured":"Mangrum R, Gerstein MT, Hall CJ 3rd, Buse DC, Houts CR, McGinley JS et al (2023) Priority acute and preventive migraine treatment benefits: results of the migraine clinical outcome assessment system (MiCOAS) qualitative study of people living with migraine. Headache 63(7):953\u2013964. https:\/\/doi.org\/10.1111\/head.14521","journal-title":"Headache"},{"issue":"10","key":"2227_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044. https:\/\/doi.org\/10.1177\/0333102420941839","journal-title":"Cephalalgia"},{"issue":"5","key":"2227_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"issue":"7","key":"2227_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/head.14151","volume":"61","author":"PM Estave","year":"2021","unstructured":"Estave PM, Beeghly S, Anderson R, Margol C, Shakir M, George G et al (2021) Learning the full impact of migraine through patient voices: A qualitative study. Headache 61(7):1004\u20131020. https:\/\/doi.org\/10.1111\/head.14151","journal-title":"Headache"},{"issue":"3","key":"2227_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/head.14484","volume":"63","author":"MT Gerstein","year":"2023","unstructured":"Gerstein MT, Wirth RJ, Uzumcu AA, Houts CR, McGinley JS, Buse DC et al (2023) Patient-reported experiences with migraine-related cognitive symptoms: results of the MiCOAS qualitative study. Headache 63(3):441\u2013454. https:\/\/doi.org\/10.1111\/head.14484","journal-title":"Headache"},{"issue":"8","key":"2227_CR7","doi-asserted-by":"publisher","first-page":"333102424127434","DOI":"10.1177\/03331024241274343","volume":"44","author":"Z Katsarava","year":"2024","unstructured":"Katsarava Z, Buse DC, Leroux E, Lanteri-Minet M, Sakai F, Matharu MS et al (2024) Disability in migraine: multicountry results from the chronic migraine epidemiology and Outcomes - International (CaMEO-I) study. Cephalalgia 44(8):3331024241274343. https:\/\/doi.org\/10.1177\/03331024241274343","journal-title":"Cephalalgia"},{"issue":"2","key":"2227_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/head.14664","volume":"64","author":"R Mangrum","year":"2024","unstructured":"Mangrum R, Bryant AL, Gerstein MT, McCarrier KP, Houts CR, McGinley JS et al (2024) The impacts of migraine on functioning: results from two qualitative studies of people living with migraine. Headache 64(2):156\u2013171. https:\/\/doi.org\/10.1111\/head.14664","journal-title":"Headache"},{"issue":"8","key":"2227_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14737175.2024.2365312","volume":"24","author":"M Vikelis","year":"2024","unstructured":"Vikelis M, Rikos D, Argyriou AA, Papachristou P, Rallis D, Karapanayiotides T et al (2024) Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints. Expert Rev Neurother 24(8):815\u2013826. https:\/\/doi.org\/10.1080\/14737175.2024.2365312","journal-title":"Expert Rev Neurother"},{"key":"2227_CR10","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (2009) https:\/\/www.fda.gov\/media\/77832\/download. Accessed September 15"},{"key":"2227_CR11","unstructured":"U.S. Food and Drug Administration. Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making (2025) https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed September 15"},{"issue":"3","key":"2227_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WCO.0000000000001267","volume":"37","author":"A Alpuente","year":"2024","unstructured":"Alpuente A, Torres-Ferrus M, Caronna E, Pozo-Rosich P (2024) The state of Art on the use of patient reported outcomes in migraine. Curr Opin Neurol 37(3):271\u2013282. https:\/\/doi.org\/10.1097\/WCO.0000000000001267","journal-title":"Curr Opin Neurol"},{"key":"2227_CR13","volume-title":"Book title. Headache","author":"DC Buse","year":"2023","unstructured":"Buse DC, Lipton RB (2023) Psychological and behavioral aspects of headache and pain. In: Yal\u0131nay Dikmen P, \u00d6zge A (eds) Current pain and headache reports, vol. 27, issue 2. Springer, Cham, p 42"},{"issue":"2","key":"2227_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/head.14069","volume":"61","author":"JS McGinley","year":"2021","unstructured":"McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ et al (2021) Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache 61(2):253\u2013262. https:\/\/doi.org\/10.1111\/head.14069","journal-title":"Headache"},{"issue":"7","key":"2227_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/head.14167","volume":"61","author":"RE Wells","year":"2021","unstructured":"Wells RE, Estave PM, Burch R, Haas N, Powers SW, Seng E et al (2021) The value of the patient perspective in Understanding the full burden of migraine. Headache 61(7):985\u2013987. https:\/\/doi.org\/10.1111\/head.14167","journal-title":"Headache"},{"issue":"8","key":"2227_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jama.284.8.1021","volume":"284","author":"W Levinson","year":"2000","unstructured":"Levinson W, Gorawara-Bhat R, Lamb J (2000) A study of patient clues and physician responses in primary care and surgical settings. JAMA 284(8):1021\u20131027. https:\/\/doi.org\/10.1001\/jama.284.8.1021","journal-title":"JAMA"},{"issue":"7","key":"2227_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40265-020-01300-4","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Eptinezumab: first approval. Drugs 80(7):733\u2013739. https:\/\/doi.org\/10.1007\/s40265-020-01300-4","journal-title":"Drugs"},{"key":"2227_CR18","doi-asserted-by":"publisher","first-page":"1355877","DOI":"10.3389\/fneur.2024.1355877","volume":"15","author":"P Irimia","year":"2024","unstructured":"Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, Lainez JM (2024) Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 15:1355877. https:\/\/doi.org\/10.3389\/fneur.2024.1355877","journal-title":"Front Neurol"},{"issue":"1","key":"2227_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-024-01764-9","volume":"25","author":"C Argoff","year":"2024","unstructured":"Argoff C, Herzog SP, Smith RM, Kotak SV, Sopina L, Saltarska Y et al (2024) Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. J Headache Pain 25(1):65. https:\/\/doi.org\/10.1186\/s10194-024-01764-9","journal-title":"J Headache Pain"},{"issue":"7","key":"2227_CR20","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/0333102417731348","volume":"38","author":"KL Haywood","year":"2018","unstructured":"Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M (2018) Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs). Cephalalgia 38(7):1374\u20131386. https:\/\/doi.org\/10.1177\/0333102417731348","journal-title":"Cephalalgia"},{"issue":"3","key":"2227_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11916-012-0263-1","volume":"16","author":"DC Buse","year":"2012","unstructured":"Buse DC, Sollars CM, Steiner TJ, Jensen RH, Al Jumah MA, Lipton RB (2012) Why HURT? A review of clinical instruments for headache management. Curr Pain Headache Rep 16(3):237\u2013254. https:\/\/doi.org\/10.1007\/s11916-012-0263-1","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"2227_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"2227_CR23","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e77. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"11","key":"2227_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11916-019-0824-7","volume":"23","author":"R Gil-Gouveia","year":"2019","unstructured":"Gil-Gouveia R, Martins IP (2019) Cognition and cognitive impairment in migraine. Curr Pain Headache Rep 23(11):84. https:\/\/doi.org\/10.1007\/s11916-019-0824-7","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"2227_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00415-014-7603-5","volume":"262","author":"R Gil-Gouveia","year":"2015","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP (2015) Assessment of cognitive dysfunction during migraine attacks: a systematic review. J Neurol 262(3):654\u2013665. https:\/\/doi.org\/10.1007\/s00415-014-7603-5","journal-title":"J Neurol"},{"issue":"5","key":"2227_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0333102415604471","volume":"36","author":"R Gil-Gouveia","year":"2016","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP (2016) The impact of cognitive symptoms on migraine attack-related disability. Cephalalgia 36(5):422\u2013430. https:\/\/doi.org\/10.1177\/0333102415604471","journal-title":"Cephalalgia"},{"issue":"1","key":"2227_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-022-01429-5","volume":"23","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gallop K, Smith T, Powell L, Johnston K, Hubig LT et al (2022) Real-World experience of interictal burden and treatment in migraine: a qualitative interview study. J Headache Pain 23(1):65. https:\/\/doi.org\/10.1186\/s10194-022-01429-5","journal-title":"J Headache Pain"},{"issue":"4","key":"2227_CR28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s11065-021-09516-1","volume":"32","author":"DL Braganza","year":"2022","unstructured":"Braganza DL, Fitzpatrick LE, Nguyen ML, Crowe SF (2022) Interictal cognitive deficits in migraine sufferers: A Meta-Analysis. Neuropsychol Rev 32(4):736\u2013757. https:\/\/doi.org\/10.1007\/s11065-021-09516-1","journal-title":"Neuropsychol Rev"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02227-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:54:44Z","timestamp":1781618084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2227"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02227-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board (IRB) approval (WCG IRB, Princeton, NJ, United States, and Ochsner Neurosciences Institute IRB, New Orleans, LA, United States) was obtained for each study site and all participants gave written informed consent prior to study participation. Prior to study participation all participants were informed of the observational study guidelines including that the interview is unblinded, not to divulge any proprietary or confidential information, that the interview was being conducted for observational research purposes only and not intended to promote any product or company, that all responses were to be aggregated with other interviewees, and to confirm their comfort in recording the conversation for note taking purposes only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fawad A. Khan reported receiving institutional research support from Biohaven, Teva, Marinus, Lundbeck, Supernus, Neurona, and UCB; advisory fees from Eisai, Neurelis, Marinus, Epitel, SK Life Science, AbbVie, Pfizer; honorarium for speaker engagements from Amgen, UCB, SK Life Science, Lundbeck, Allergan, Lilly USA, Pfizer, Impel Pharmaceuticals, AbbVie; honorarium for educational programs from Natus and Stratus. He serves on the Louisiana State Medical Advisory Board in a non-paid position. In non-compensated roles, he is a board member of the Deccan Alumni Association of North America. Steven P. Herzog reports receiving honoraria for speaker engagements from AbbVie. Ryan M. Smith reports no conflicts. Dawn C. Buse has received grant support from Amgen, the National Headache Foundation, and the US Food and Drug Administration; has served as a consultant and received honoraria from Allergan\/AbbVie, Amgen\/Novartis, Biohaven, Collegium, Eli Lilly, Lundbeck, Pfizer, Teva, and Theranica; and has served on the editorial board of Current Pain and Headache Reports. Seema Soni-Brahmbhatt, Susanne F. Awad, S. Wald Grossman, Divya Asher, and Foram Patel are full-time employees of Lundbeck LLC or H. Lundbeck A\/S. Charles Argoff has served as a consultant for Vertex, X Gene Pharma, OPC, Scilex, GSK and has received honoraria from AbbVie, Averitas, Lundbeck, and Scilex; research grants from Lilly, Abbvie, Vertex, and Lundbeck; and has received royalties from Elsevier for Pain Management Secrets and Raj\u2019s Practical Management of Pain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}